The estimated Net Worth of Frances Arnold is at least $4.35 Milión dollars as of 30 April 2024. Frances Arnold owns over 80 units of Illumina Inc stock worth over $1,941,231 and over the last 9 years he sold ILMN stock worth over $1,923,887. In addition, he makes $481,850 as Independent Director at Illumina Inc.
Frances has made over 20 trades of the Illumina Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 80 units of ILMN stock worth $13,390 on 30 April 2024.
The largest trade he's ever made was selling 1,503 units of Illumina Inc stock on 11 May 2020 worth over $464,592. On average, Frances trades about 236 units every 67 days since 2016. As of 30 April 2024 he still owns at least 15,551 units of Illumina Inc stock.
You can see the complete history of Frances Arnold stock trades at the bottom of the page.
Dr. Frances Arnold, Ph.D. is an Independent Director of Illumina, Inc. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academics of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.
As the Independent Director of Illumina Inc, the total compensation of Frances Arnold at Illumina Inc is $481,850. There are 16 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Frances Arnold is 63, he's been the Independent Director of Illumina Inc since 2016. There are 3 older and 19 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Frances's mailing address filed with the SEC is C/O ALPHABET INC., 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW, CA, 94043.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley a Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: